News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Wuxi Fortune Partners With Andarix To Develop Radiotherapeutic In China



9/7/2017 10:49:59 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Wuxi Fortune Pharma partnered with Andarix Pharma of Boston to develop Tozaride, a radiolabeled cancer drug candidate, in China. Tozaride combines a somatostatin peptide with a high-energy, beta-emitting radionuclide, Rhenium-188. The peptide binds to lung and neuroendocrine cancers. In the US, Andarix has completed three clinical trials of Tozaride in patients with refractory lung cancer. Fortune will own certain specific marketing rights to Tozaride in China, though the details of the agreement were not disclosed.

Read at ChinaBio Today


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES